Trace Wealth Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$396K Sell
1,575
-25
-2% -$5.38K 0.26% 45
2026
Q1
$348K Sell
1,600
-144
-8% -$31.9K 0.26% 49
2025
Q4
$398K Sell
1,744
-38
-2% -$8.66K 0.29% 45
2025
Q3
$413K Buy
1,782
+131
+8% +$26.7K 0.31% 44
2025
Q2
$306K Buy
1,651
+31
+2% +$5.76K 0.25% 48
2025
Q1
$339K Hold
1,620
0.3% 45
2024
Q4
$288K Buy
+1,620
New +$298K 0.26% 49

Other funds holding ABBV

Trace Wealth Advisors's ABBV Position: Q2 2026 in Review

Trace Wealth Advisors reduced its AbbVie (ABBV) stake by 1.6% in Q2 2026, selling an estimated $5.38K and leaving 1,575 shares worth $396K. The position accounts for 0.26% of the portfolio, ranked #45.

Trace Wealth Advisors first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $413K in Q3 2025. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Trace Wealth Advisors held 1,575 shares of AbbVie worth $396K as of Q2 2026.
  • Trace Wealth Advisors sold 25 AbbVie shares in Q2 2026, an estimated $5.38K.
  • AbbVie made up 0.26% of Trace Wealth Advisors's portfolio in Q2 2026, its #45 holding.
  • Trace Wealth Advisors first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
  • Trace Wealth Advisors's AbbVie position peaked at $413K in Q3 2025.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Trace Wealth Advisors's 13F filing for Q2 2026, filed 28 Jul 2026.